Accent Therapeutics appoints Serena Silver as chief scientific officer as it advances Phase I/II ATX-559 trials for advanced ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...

Merck KGaA appoints Miguel Fernández Alcalde as president of its US biopharmaceutical division EMD Serono to strengthen the ...

Minoryx Therapeutics plans to submit European approval for leriglitazone after Phase II NEXUS trial shows 35% disease arrest ...

Santhera Pharmaceuticals gains approval in China for Agamree, the first Duchenne muscular dystrophy therapy available for ...

Shares of US clinical stage biopharma Candel Therapeutics leapt 166% to $12.25 in pre-market activity today, after it ...

US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating ...

Indian drugmaker Dr Reddy’s Laboratories has recently become the first Indian company to launch checkpoint inhibitor Zytorvi ...

Netherlands-based Pharming Group today released positive top-line results of data from its Phase III clinical trial ...

Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful ...

Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...